These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34361048)

  • 1. Phytochemicals in Malignant Pleural Mesothelioma Treatment-Review on the Current Trends of Therapies.
    Chmielewska-Kassassir M; Wozniak LA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyphenol Extract from Evening Primrose (
    Chmielewska-Kassassir M; Sobierajska K; Ciszewski WM; Bukowiecka-Matusiak M; Szczesna D; Burzynska-Pedziwiatr I; Wiczkowski W; Wagner W; Wozniak LA
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
    Cakiroglu E; Senturk S
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the anticancer potential of Polygonum multiflorum root-derived stilbenes against H2452 malignant pleural mesothelioma cells.
    Ngo TH; Lee YJ; Choi H; Song KS; Lee KJ; Nam JW
    Fitoterapia; 2024 Sep; 177():106135. PubMed ID: 39047845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells.
    Gesmundo I; Silvagno F; Banfi D; Monica V; Fanciulli A; Gamba G; Congiusta N; Libener R; Riganti C; Ghigo E; Granata R
    Front Endocrinol (Lausanne); 2020; 11():559586. PubMed ID: 33133014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant Mesothelioma and Delivery of Polyphenols.
    Bishop KS; Braakhuis AJ; Ferguson LR
    Nutrients; 2016 Jun; 8(6):. PubMed ID: 27271656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in treatment of mesothelioma.
    Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
    Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.
    Burgio S; Noori L; Marino Gammazza A; Campanella C; Logozzi M; Fais S; Bucchieri F; Cappello F; Caruso Bavisotto C
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is DNA repair a potential target for effective therapies against malignant mesothelioma?
    Fuso Nerini I; Roca E; Mannarino L; Grosso F; Frapolli R; D'Incalci M
    Cancer Treat Rev; 2020 Nov; 90():102101. PubMed ID: 32892058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
    Liu H; Wu L; Ji K; Wang W
    Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic alterations in malignant pleural mesothelioma cells in response to long‑term treatment with bullfrog sialic acid‑binding lectin.
    Tatsuta T; Nakasato A; Sugawara S; Hosono M
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
    Zhang X; Yang L; Chen W; Kong M
    Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
    Hylebos M; Van Camp G; van Meerbeeck JP; Op de Beeck K
    J Thorac Oncol; 2016 Oct; 11(10):1615-26. PubMed ID: 27282309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic features of erionite-induced malignant mesothelioma.
    Demirer E; Ghattas CF; Radwan MO; Elamin EM
    Yonsei Med J; 2015 Mar; 56(2):311-23. PubMed ID: 25683976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting multiple myeloma with natural polyphenols.
    Pojero F; Poma P; Spanò V; Montalbano A; Barraja P; Notarbartolo M
    Eur J Med Chem; 2019 Oct; 180():465-485. PubMed ID: 31330448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.